Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levalbuterol
Drug ID BADD_D01262
Description Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Indications and Usage Levosalbutamol's bronchodilator properties give it indications in treatment of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB13139
KEGG ID D08124
MeSH ID D064412
PubChem ID 123600
TTD Drug ID D02ZJI
NDC Product Code 0093-4147; 0378-9692; 63187-953; 0093-4145; 70518-2760; 65862-942; 0378-9690; 65862-943; 68071-2340; 0378-6993; 65862-944; 0093-4148; 0378-9691; 65862-945; 0093-4146
Synonyms Levalbuterol | Xopenex | Levalbuterol Hydrochloride | Hydrochloride, Levalbuterol | Levosalbutamol Hydrochloride | Hydrochloride, Levosalbutamol
Chemical Information
Molecular Formula C13H21NO3
CAS Registry Number 34391-04-3
SMILES CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema08.01.07.006; 14.05.06.010--Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
Paraesthesia17.02.06.005--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Supraventricular tachycardia02.03.03.012--
Syncope02.01.02.008; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
Tremor17.01.06.002--
Type I hypersensitivity10.01.03.006--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Wheezing22.03.01.009--
Eye pruritus06.04.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Cardiovascular function test13.14.02.013--Not Available
Electrocardiogram change13.14.05.014--Not Available
Central nervous system stimulation25.04.01.001--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
The 3th Page    First    Pre   3    Total 3 Pages